Acute non-lymphocytic leukemia (ANLL) in adult for remission induction in untreated, relapsed or refractory patients; acute lymphocytic leukemia (ALL) as 2nd-line treatment in adult & childn.
Adult ANLL 12 mg/m2 IV daily for 3 days in combination w/ cytarabine or 8 mg/m2 IV daily for 5 days as single agent or in combination. ALLAdult 12 mg/m2 single dose IV daily for 3 days. Childn 10 mg/m2 single dose IV daily for 3 days.
View Zavedos overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to idarubicin, other anthracyclines or anthracenediones. Severe myocardial insufficiency & arrhythmias. Recent MI. Persistent myelosuppression. Previous treatment w/ max cumulative doses of idarubicin &/or other anthracyclines & anthracenediones. Severe hepatic & renal impairment.
Early/delayed cardiotoxicity; active or dormant CV disease, prior or concomitant radiotherapy to mediastinal/pericardial area, previous therapy w/ other anthracyclines or anthracenediones & concomitant use of drugs w/ ability to suppress cardiac contractility or cardiotoxic drugs eg, trastuzumab. Severe myelosuppression. Secondary leukemia, GI complications, tumor lysis syndrome, thrombophlebitis & thromboembolic phenomena. Inj site effects, extravasation. Assess cardiac function, hematologic profile before & during treatment. Evaluate blood uric acid, K, Ca phosphate & creatinine levels after initial treatment. Avoid use w/ live vaccine. Hepatic &/or renal impairment. Women of childbearing potential. May impair fertility in men. Pregnancy. Not to be used during lactation.
Manage Account
Change Password
Sign Out
